Douglas Forsyth

Douglas Forsyth has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Virtus Equity & Convertible Income Fund, Inhibrx Biosciences, Inc. and Inhibrx, Inc. Over a trading history stretching from 11 August 2020 to 8 September 2026, the count stands at 15 filings.

In open-market terms, that means 3 purchases worth €1.2M on one side and 9 sales worth €420k on the other. On balance, insiders were net buyers of €759k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant. In 2026 alone, the filings show 1 purchase and no sales.

The median purchase comes to €246k. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

On 8 September 2026 came the latest disclosure, an open-market purchase for €246k in Inhibrx Biosciences, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.